Anti-eIF4A2 (Eukaryotic Initiation Factor 4A-II, eIF-4A-II, eIF4A-II, ATP-dependent RNA Helicase eIF

eIF4A2 is a 407aa ATP-dependent RNA helicase, belonging to the DEAD box helicase family. It contains one helicase ATP-binding domain and a helicase C-terminal domain. eIF4A2, a subunit of the eIF4F complex, acts as a protein-synthesis initiation factor and thus plays an important role in the binding of mRNA to the 43S pre-initiation complex of ribosomes. Research is carried out to elucidate the potential role of eIF4A2 in glucose homeostasis and also in type 2 diabetes in the presence of metabolic stress where eIF4A2 controls specific mRNA translation and protein synthesis rate in pancreatic beta-cells. Human eIF4A2 interacts with the NS5B protein of Hepatitis C virus (HCV) and facilitates the genomic RNA synthesis of NS5B protein by unwinding the secondary structure of the HCV genome. It is ubiquitously expressed in most of normal tissues, but in variable amount. Applications: Suitable for use in Western Blot. Other applications not tested. Recommended Dilution: Western Blot: 0.025-0.05ug/ml, Optimal dilutions to be determined by the researcher. Positive Control: Jurkat and 3T3 cell lysates, Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.